Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte [cytarabine] by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis.

Trial Profile

Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte [cytarabine] by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Cytarabine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Folinic acid; Methotrexate; Prednisolone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2017 This trial has been completed in Belgium as per European Clinical Trials Database record.
    • 03 Jul 2012 Baxter International, Dakota Pharm, Merck, Pfizer, Roche, Sandoz, SkyePharma PLC added as associations as reported in the European Clinical Trials Database record.
    • 03 Jul 2012 Additional trial location (Belgium) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top